Jared Kaltwasser

A new report tracking patients suggests that even those who return to work experience persistent symptoms.

The data may help explain why COVID-19 patients experience dangerous secondary infections.

The study showed, however, that physicians can help solve the problem if they are willing to answer patient’s questions about the therapy’s efficacy and safety.

A new report finds veterans who took vitamin D supplements were less likely to get COVID-19 and less likely to die within 30 days of infection.

As viral hepatitis is the most common blood-transmitted infection globally, assessing the toll of hepatitis and hepatitis-related conditions is critical.

The company says it plans to begin talking with regulators next year after seeing positive efficacy data in the trials.

The closely watched therapeutic candidate led to long-term responses in 90% of patients who benefited from the therapy.

November is Clostridioides difficile (C diff) awareness month. The Peggy Lillis Foundation hopes to use the month to increase the public’s awareness of the dangers of the infection.

Over the past decade, the number of cases of hepatitis A infection at a Turkish hospital has decreased, but a growing proportion of cases come from migrants to the country.

A new review article suggests it is possible to eradicate hepatitis C virus infections among people with hemophilia, but it will take intense focus from public health agencies.

Interim data show a bivalent vaccine that contains the Omicron variant may be more effective.

There are a number of programs designed to help lower rates of infection and transmission amongst this industry's workforce in South Africa.

When physicians were told that a case was likely viral they were less likely to prescribe antibiotics, a new study shows.

A new report underscores a persistent problem of patients not receiving antivirals despite their high curative rate.

People who initially received an mRNA vaccine but were boosted with the Janssen vaccine had superior immune responses, the study found.

The study was longitudinal in nature, comparing at-risk people who became infected with HIV to at-risk people who did not.

The model suggests screening unvaccinated students could reduce absences by 80% compared to reactively closing classes with infected students.

Though all racial and ethnic groups saw declines in life expectancy, the impact was greater among members of minority groups.

The report showed the protective benefits varied somewhat by cardiovascular disease subtype.

A new analysis from a Massachusetts health system found in-hospital infections occurred at a higher rate when the Omicron variant was present compared to when wild-type SARS-CoV-2 was prevalent.

Patients with a history of infection who were also vaccinated had the strongest protection, the data showed.

Rather than developing vaccines for each new variant, some officials are pushing to follow the flu vaccine model, with annual vaccination.

Patients who took RBX2660 following antibiotic therapy had lower rates of recurrence and double the time to recurrence, compared to patients taking placebo.

The microbiota-based live therapeutic had a 68.3% success rate when administered following antibiotic treatment, versus a 55% success rate in a placebo group.

Most of the discussion around fecal microbiota transplantation has focused on bacterial communities, but new advances have shed more light on the role of the virome.

About 65% of patients with metronidazole-resistant recurrent C difficile infection benefitted from taking rifaximin.

In a mouse model, the product protected against C difficile without eliminating the antibiotic’s presence in the blood.

The technology platform could speed up the development of novel therapeutics to combat virulence.

In a small retrospective study, 7 of 11 patients experienced clinical improvement.

Nearly 8 in 10 patients with recurrent C. diff. Infection were successfully treated after up to 2 doses of the microbiota-based therapy.